Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I dose-escalation study of mitoxantrone liposome combined with cytarabine and etoposide in relapsed or refractory acute myeloid leukemia
ChiCTR2200060085Phase 4Recruiting
- Sponsor
- Union Hospital
- Start
- Mar 2022
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of mitoxantrone-liposome, cytarabine and etoposide in acute myeloid leukemia (AML), sponsored by Union Hospital. Primary endpoint: Maximum tolerated dose of mitoxantrone liposome. Started Mar 2022; status: recruiting.
02
Drugs
mitoxantrone-liposomecytarabineetoposide
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR2200060085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200060085.